TS-000859 — Nephrotic syndrome (NS) is a common kidney disease found in children that creates an overabundance of protein in the urine, comparable to proteinuria in adults. As of now, there are no approved safe and effective treatment for NS, especially for those whose NS is steroid or multi-drug resistant. A team of researchers have identified a series of new molecular targets for future drug development. Using glomerular transcriptomes and informatic analysis, clinicians will be able to identify immunosuppressive approaches that are distinct from the current procedures.

TS-000737 — Nephrotic syndrome (NS) is a common kidney disease found in children that creates an overabundance of protein in the urine, comparable to proteinuria in adults. As of now, there are no approved safe and effective treatment for NS, especially for those whom NS is steroid or multi-drug resistant. Current treatments for NS are only partially effective and often create notable toxicity, but existing thiazolidinediones (TZDs) used for proteinuria in adults have resulted in reduction of proteins found in the urine. Introducing the TZD pioglitazone (PIO) to a trial study conducted by Dr. William Smoyer, pediatric patients with multi-drug resistant NS showed notable proteinuria reduction in comparable time periods, both before and after the addition of PIO in their medical regimens.